ライフサイエンスコーパス: acute ischemic stroke

1 after usual care versus usual care alone for acute ischemic stroke.

2 rovide neuroprotection in an animal model of acute ischemic stroke.

3 ecommended strategies to reduce DTN times in acute ischemic stroke.

4 ients and providers in considering r-tPA for acute ischemic stroke.

5 ombolysis remains the mainstay treatment for acute ischemic stroke.

6 tributor to delays in timely tPA therapy for acute ischemic stroke.

7 me to thrombolysis is crucial for outcome in acute ischemic stroke.

8 TN) time within 60 minutes for patients with acute ischemic stroke.

9 ht of the severe underuse of thrombolysis in acute ischemic stroke.

10 They had the signature features of acute ischemic stroke.

11 lity and functional outcome in patients with acute ischemic stroke.

12 ta on its impact in endovascular therapy for acute ischemic stroke.

13 that can decrease ITN time for patients with acute ischemic stroke.

14 at discharge and discharge to home following acute ischemic stroke.

15 ed to translate to efficacious therapies for acute ischemic stroke.

16 outcome in patients treated with IV tPA for acute ischemic stroke.

17 meningeal collateral status in patients with acute ischemic stroke.

18 n and extend the therapeutic time window for acute ischemic stroke.

19 meningeal collateral status in patients with acute ischemic stroke.

20 essment as a neuroprotective agent following acute ischemic stroke.

21 alteplase is the only approved treatment for acute ischemic stroke.

22 anaging hypertensive patients suffering from acute ischemic stroke.

23 ntriguing treatment options in patients with acute ischemic stroke.

24 to improve the timeliness of reperfusion in acute ischemic stroke.

25 adults (aged 15-44 years) hospitalized with acute ischemic stroke.

26 ) is used for the treatment of patients with acute ischemic stroke.

27 PA as a thrombolytic agent in the setting of acute ischemic stroke.

28 the evaluation and treatment of adults with acute ischemic stroke.

29 approved by the FDA for use in patients with acute ischemic stroke.

30 europrotection as a therapeutic strategy for acute ischemic stroke.

31 timuli have emerged as important triggers of acute ischemic stroke.

32 r it would reduce disability in humans after acute ischemic stroke.

33 eported to correlate with poor outcome after acute ischemic stroke.

34 window for effective thrombolytic therapy in acute ischemic stroke.

35 inogen activator) for selected patients with acute ischemic stroke.

36 esently under evaluation in the treatment of acute ischemic stroke.

37 ic issues in the management of patients with acute ischemic stroke.

38 rable benefit-risk profile for patients with acute ischemic stroke.

39 ed mortality in critically ill patients with acute ischemic stroke.

40 rstanding of the evolution and outcome after acute ischemic stroke.

41 d to attempt maximum rates of recovery after acute ischemic stroke.

42 t be withheld in these complex patients with acute ischemic stroke.

43 r conventional treatment (control group) for acute ischemic stroke.

44 16, and received mechanical thrombectomy for acute ischemic stroke.

45 ssion levels are differentially regulated in acute ischemic stroke.

46 ve prothrombolytic potential in treatment of acute ischemic stroke.

47 y of a translational thromboembolic model of acute ischemic stroke.

48 t of endovascular treatment in patients with acute ischemic stroke.

49 ground breaking changes in the treatment of acute ischemic stroke.

50 mbra from the ischemic core in patients with acute ischemic stroke.

51 protect neonatal brain from hemorrhage after acute ischemic stroke.

52 ssociation between serum UA and prognosis of acute ischemic stroke.

53 uPAR promotes neurological recovery after an acute ischemic stroke.

54 e, which might become useful in treatment of acute ischemic stroke.

55 n M2 occlusions in a cohort of patients with acute ischemic stroke.

56 atelet therapy before tPA administration for acute ischemic stroke.

57 udy from the China Antihypertensive Trial in Acute Ischemic Stroke.

58 C potentiates neuroinflammatory responses to acute ischemic stroke.

59 arct size in acute myocardial infarction and acute ischemic stroke.

60 Administration in 1996 for the treatment of acute ischemic stroke.

61 compared with alteplase for the treatment of acute ischemic stroke, 1 that demonstrated superiority o

62 Among 30,947 patients with acute ischemic stroke, 15,297 (49.4%) were admitted to d

63 e (38%), intracerebral hemorrhage (31%), and acute ischemic stroke (18%).

64 , we identified 554 ventilated patients with acute ischemic stroke (19%), 936 ventilated patients wit

65 Of all patients with acute ischemic stroke, 26% required ICU admission.

66 Of 29 618 patients with acute ischemic stroke, 283 (1.0%) were treated within 4.

67 a on 220 patients with DM who presented with acute ischemic stroke, 43 of whom were managed with and

68 Among patients with acute ischemic stroke, admission to a designated stroke

69 HSS documentation in 1 184 288 patients with acute ischemic stroke admitted to 1704 GWTG-Stroke hospi

70 d long-term mortality in older patients with acute ischemic stroke admitted to ICUs is lower than pre

71 as a strategy to reduce the consequences of acute ischemic stroke (AIS) and NMDA receptors remain a

72 Timely reperfusion is critical in acute ischemic stroke (AIS) and ST-segment-elevation myo

73 plasminogen activator (tPA) in patients with acute ischemic stroke (AIS) are time dependent and guide

74 Acute Ischemic Stroke (AIS) can be cured by trombolytic

75 improves clinical outcomes in patients with acute ischemic stroke (AIS) caused by a large vessel occ

76 5.9 years +/- 12.3; range, 25-86 years) with acute ischemic stroke (AIS) due to middle cerebral arter

77 A relevant proportion of patients with acute ischemic stroke (AIS) have elevated levels of card

78 ry (cICA) occlusion is a recognized cause of acute ischemic stroke (AIS) in sickle cell disease (SCD)

79 Acute ischemic stroke (AIS) is the leading cause of disa

80 ates of tPA use over time among hospitalized acute ischemic stroke (AIS) patients.

81 olized rabbits and clinical rating scores in acute ischemic stroke (AIS) patients; however, the cellu

82 on between thyroid hormones and prognosis of acute ischemic stroke (AIS) reported conflicting results

83 Patients with acute ischemic stroke (AIS) suffer from infections assoc

84 acerebral hemorrhage (sICH) in patients with acute ischemic stroke (AIS) treated with intravenous thr

85 is known as to whether long-term outcomes of acute ischemic stroke (AIS) vary by race/ethnicity.

86 al thrombectomy (MT) is recommended to treat acute ischemic stroke (AIS) with a large vessel occlusio

87 factor for coronary artery disease (CAD) and acute ischemic stroke (AIS), but there are numerous repo

88 They are also frequently observed after acute ischemic stroke (AIS), indicating poor functional

89 e TSC is a promising drug candidate to treat acute ischemic stroke (AIS), we tested the hypothesis th

90 efficient use of intravenous thrombolysis in acute ischemic stroke (AIS).

91 timating clinical outcomes for patients with acute ischemic stroke (AIS).

92 issue plasminogen activator (tPA) therapy in acute ischemic stroke (AIS).

93 window from 3 to 4.5 hours for patients with acute ischemic stroke (AIS).

94 ted with better neurologic outcome following acute ischemic stroke (AIS).

95 a promising alternative for the treatment of acute ischemic stroke (AIS).

96 Patients who presented with acute ischemic stroke and a large vessel occlusion in th

97 There were 187 patients with acute ischemic stroke and continuous heart rhythm monito

98 gnettes in which they had either suffered an acute ischemic stroke and could be treated with thrombol

99 e been receiving antiplatelet therapy before acute ischemic stroke and could face an increased risk f

100 t is particularly sensitive for detection of acute ischemic stroke and differentiation of acute strok

101 terpretation of magnetic resonance images of acute ischemic stroke and how they are used to select pa

102 echocardiography in 255 patients with first acute ischemic stroke and in 209 control subjects matche

103 e observational study of 94474 patients with acute ischemic stroke and known history of AF admitted f

104 ta in 100 patients with anterior-circulation acute ischemic stroke and large vessel occlusion who und

105 essful revascularization among patients with acute ischemic stroke and large vessel occlusion.

106 Medical Center in Nashville, Tennessee, with acute ischemic stroke and later received a diagnosis of

107 Outcomes for some patients with acute ischemic stroke and moderate to severe neurologica

108 hanical thrombectomy in select patients with acute ischemic stroke and proximal artery occlusions has

109 lts suggest that CEPO may be useful to treat acute ischemic stroke and supports the study of CEPO in

110 urrent stroke and cardiovascular outcomes in acute ischemic stroke and transient ischemic attack (TIA

111 re most likely to benefit from therapies for acute ischemic stroke and whether endovascular thrombect

112 All 3 patients presented with acute ischemic strokes and had a history of epidural spi

113 Patients with acute ischemic strokes and LVO in M2 segments presenting

114 rospective cohort study pooled patients with acute ischemic strokes and LVO isolated to M2 segments f

115 proved in the United States for treatment of acute ischemic stroke, and has limitations.

116 ave evaluated hypothermia as a treatment for acute ischemic stroke, and no controlled trials of hypot

117 ogen activator (tPA) is the only therapy for acute ischemic stroke approved by the Food and Drug Admi

118 All patients with acute ischemic stroke are in need of hyperacute secondar

119 s tissue-type plasminogen activator (tPA) in acute ischemic stroke are time dependent, and guidelines

120 venous tissue-plasminogen activator (tPA) in acute ischemic stroke are time-dependent.

121 Acute ischemic strokes are associated with poor outcomes

122 tiganel was not efficacious in patients with acute ischemic stroke at either of the tested doses, and

123 estigate the outcomes of patients who had an acute ischemic stroke attributed to an anterior circulat

124 is decisions for incapacitated patients with acute ischemic stroke because the risks and benefits of

125 Among patients with acute ischemic stroke, black patients had lower mortalit

126 (rt-PA) improves outcomes for patients with acute ischemic stroke, but current approved use is limit

127 of endovascular therapy to standard care for acute ischemic stroke, but pointed out to the need and d

128 Thrombolysis is widely used to intervene in acute ischemic stroke, but reestablishment of circulatio

129 rtension are correlated with poor outcome in acute ischemic stroke, but the effect of reducing or aug

130 (t-PA) for patients with moderate-to-severe acute ischemic stroke, but whether a combined approach i

131 for Medicare beneficiaries hospitalized with acute ischemic stroke, but whether it is necessary to in

132 ovide neuroprotection in mechanical model of acute ischemic stroke by inducing hypothermia, a conditi

133 METHODS AND Acute ischemic stroke cases entered into GWTG (Get With

134 In patients with acute ischemic stroke caused by a proximal intracranial

135 In patients with acute ischemic stroke caused by a proximal intracranial

136 Intra-arterial treatment (IAT) for acute ischemic stroke caused by intracranial arterial oc

137 favorable clinical outcomes in patients with acute ischemic stroke caused by intracranial proximal oc

138 ciated with better outcomes in patients with acute ischemic stroke caused by large artery occlusion.

139 th IA r-proUK within 6 hours of the onset of acute ischemic stroke caused by MCA occlusion significan

140 Acute ischemic stroke caused by proximal intracranial ar

141 An algorithm using only acute ischemic stroke codes (433.x1, 434.x1, 436) had a

142 trials comparing endovascular treatment for acute ischemic stroke compared to the previous standard

143 ke risk factors among those hospitalized for acute ischemic stroke continued to increase from 2003-20

144 In patients with acute ischemic stroke, continuous transcranial Doppler a

145 The clusters identified show promise for acute ischemic stroke detection.

146 vestinel administered up to 6 hours after an acute ischemic stroke did not improve functional outcome

147 The majority of patients with acute ischemic stroke do not receive any form of reperfu

148 of symptomatic carotid web in patients with acute ischemic stroke due to intracranial large vessel o

149 In acute ischemic stroke due to large artery occlusion, mec

150 n were observed in 2.5% of the patients with acute ischemic stroke due to large vessel occlusion and

151 We treated all patients who had acute ischemic stroke due to occlusion of the middle cer

152 Among patients with acute ischemic stroke due to occlusions in the proximal

153 In patients receiving intravenous t-PA for acute ischemic stroke due to occlusions in the proximal

154 onsiderations of intra-arterial treatment of acute ischemic stroke emphasizes the need for well desig

155 0 045 consecutive emergency department-based acute ischemic stroke encounters arriving </= 3 hours af

156 Among patients with acute ischemic stroke, endovascular therapy with mechani

157 patients aged 18 to 45 years with first-ever acute ischemic stroke enrolled in the multicenter Italia

158 For acute ischemic stroke, fibrinolysis is the only treatmen

159 However, 23% to 40% of ideal candidates with acute ischemic stroke for reperfusion are not treated, p

160 has been the key treatment for patients with acute ischemic stroke for the past decade.

161 ble and recommended treatment modalities for acute ischemic stroke from an interdisciplinary perspect

162 of a telestroke network in the management of acute ischemic stroke from the perspectives of a network

163 plasminogen activator (tPA) in patients with acute ischemic stroke, guidelines recommend door-to-imag

164 Streptokinase therapy for acute ischemic stroke has not been shown to be effective

165 The treatment of acute ischemic stroke has undergone dramatic changes rec

166 Recent clinical trials in adults with acute ischemic stroke have demonstrated increased mortal

167 Several trials involving patients with acute ischemic stroke have shown better functional outco

168 indings in this study are as follows: first, acute ischemic stroke hospitalization rates increased si

169 health risk behaviors were identified among acute ischemic stroke hospitalizations in young adults.

170 Endovascular intervention for acute ischemic stroke improves revascularization.

171 oral trends, and early clinical outcomes for acute ischemic stroke in a large contemporary cohort.

172 A small proportion of patients admitted with acute ischemic stroke in Cleveland received tPA; they ex

173 esearch, we developed a preclinical model of acute ischemic stroke in dogs.

174 anical thrombectomy with stent retrievers in acute ischemic stroke in the anterior circulation in ter

175 nclusions and Relevance: Among patients with acute ischemic stroke in the anterior circulation underg

176 14-February 2016) included 150 patients with acute ischemic stroke in the anterior circulation, highe

177 Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands (MR CLEAN) in w

178 Clinical Trial of Endovascular Treatment of Acute Ischemic Stroke in the Netherlands (MR CLEAN) was

179 Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands (MR CLEAN).

180 Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands.

181 clinical trial of endovascular treatment for acute ischemic stroke in the Netherlands.

182 Approved treatment options for acute ischemic stroke in the United States and Canada ar

183 tion of increasing hospitalization rates for acute ischemic stroke in young adults coexistent with in

184 h atrial fibrillation who had experienced an acute ischemic stroke, inadequate therapeutic anticoagul

185 advances in the treatment and prevention of acute ischemic stroke, including the current state of en

186 study, the prevalence of hospitalizations of acute ischemic stroke increased among all age and gender

187 issue plasminogen activator (IV tPA) use for acute ischemic stroke increased in Massachusetts in asso

188 The results of this trial in patients with acute ischemic stroke indicate that endovascular therapy

189 iscussed, including thrombolytic therapy for acute ischemic stroke, induced hypothermia for comatose

190 Consecutive patients with acute ischemic stroke initially admitted to a non-thromb

191 system successfully classifies patients with acute ischemic stroke into determined etiologic categori

192 Acute ischemic stroke is a leading cause of serious disa

193 chemic stroke is rapidly developing.Although acute ischemic stroke is a major cause of adult disabili

194 Acute ischemic stroke is a major cause of mortality and

195 Acute ischemic stroke is associated with high concentrat

196 t the intra-arterial thrombolytic therapy of acute ischemic stroke is at least as effective as intrav

197 sedation and airway during thrombectomy for acute ischemic stroke is controversial due to lack of ev

198 ed data, additional research on treatment of acute ischemic stroke is needed.

199 The management of acute ischemic stroke is rapidly developing.Although acu

200 Intravenous thrombolysis (IVT) for acute ischemic stroke is subject to label and guideline

201 A major limitation in thrombolysis for acute ischemic stroke is the restricted time window for

202 The most promising therapy for acute ischemic stroke is the use of a thrombolytic agent

203 The only treatment of patients with acute ischemic stroke is thrombolytic therapy, which ben

204 effectiveness of intravenous thrombolysis in acute ischemic stroke is time dependent.

205 s tissue-type plasminogen activator (tPA) in acute ischemic stroke is time dependent.

206 The treatment of acute ischemic stroke is very similar to acute myocardia

207 d-based biomarkers with clinical utility for acute ischemic stroke (IS).

208 In patients presenting with acute ischemic stroke, large aortic plaques are associat

209 ) is associated with reduced mortality after acute ischemic stroke, less is known about severe obesit

210 iterature regarding anesthetic management in acute ischemic stroke lies in the sedation level.

211 VIEW: Efforts in intra-arterial treatment of acute ischemic stroke mainly focus on new devices to rep

212 Intravenous thrombolysis is the mainstay of acute ischemic stroke management for any patient with di

213 fficacy of intravenous t-PA in patients with acute ischemic stroke may be enhanced in patients who ha

214 Early predictors of poor outcome after acute ischemic stroke may be useful in selecting patient

215 Cleveland community experience with tPA for acute ischemic stroke may differ from that reported in c

216 with diabetes mellitus (DM) presenting with acute ischemic stroke might influence the incidence of H

217 hibits remarkable neuroprotection in a mouse acute ischemic stroke model.

218 ompared mortality for patients admitted with acute ischemic stroke (n = 30,947) between 2005 and 2006

219 Patients with acute ischemic stroke (n=1791) >/=45 years were identifi

220 the genotype distributions of patients with acute ischemic stroke (n=519) and healthy control subjec

221 tially benefit from endovascular therapy for acute ischemic stroke, nor was embolectomy shown to be s

222 All patients hospitalized with acute ischemic stroke or intracerebral hemorrhage in a l

223 e plasminogen activator (IV tPA) therapy for acute ischemic stroke outside a trial setting.

224 Consecutive acute ischemic stroke patients (1,645 patients; Acute ST

225 m that treatment disparities exist for older acute ischemic stroke patients and that the rates of thr

226 he neurologic deficit and quality of life of acute ischemic stroke patients and that the therapeutic

227 of life and brain functional connectivity in acute ischemic stroke patients and to explore the mechan

228 We analyzed 99 acute ischemic stroke patients scanned within 6 hours of

229 Data from acute ischemic stroke patients treated with tPA within 3

230 An intent-to-treat population of 613 acute ischemic stroke patients was enrolled, with 547 of

231 A total of 194 samples from 76 acute ischemic stroke patients were analyzed.

232 One third of acute ischemic stroke patients were functionally depende

233 In total, 44 acute ischemic stroke patients were randomly divided to

234 INTRODUCTION: We aimed to identify whether acute ischemic stroke patients with known complete reper

235 ular therapy is an appropriate treatment for acute ischemic stroke patients within the t-PA window wh

236 Of 4782 acute ischemic stroke patients, 282 were underweight (BM

237 travenous thrombolysis) in the management of acute ischemic stroke patients.

238 imaging (PWI) can rapidly detect lesions in acute ischemic stroke patients.

239 on for determining brain tissue viability in acute ischemic stroke patients.

240 c rate of oxygen utilization (MR-CMRO(2)) in acute ischemic stroke patients.

241 Baseline UA levels were measured in 3284 acute ischemic stroke patients.

242 bectomy with the use of a stent retriever in acute ischemic stroke, performed by using a balloon guid

243 ood samples were drawn from 10 patients with acute ischemic stroke presenting within 24 h of symptom

244 We conclude that, in diabetic patients with acute ischemic stroke, prior and continued use of SU dru

245 of the literature relating to reperfusion in acute ischemic stroke published within the last year pro

246 DTN times for tPA treatment in patients with acute ischemic stroke remain suboptimal.

247 e stent retriever technique in patients with acute ischemic stroke remain uncertain because of lack o

248 The effective treatment of acute ischemic stroke remains an important goal of moder

249 ween serum uric acid (UA) and outcomes after acute ischemic stroke remains debatable in human studies

250 Management of patients with acute ischemic stroke remains multifaceted and includes

251 Patients with acute ischemic stroke require immediate diagnostic worku

252 nt is now the new standard for patients with acute ischemic stroke resulting from proximal vessel occ

253 NXY-059 within six hours after the onset of acute ischemic stroke significantly improved the primary

254 nistration-approved thrombolytic therapy for acute ischemic stroke since 1996, thrombolysis remains u

255 ogen activator, the only approved therapy of acute ischemic stroke still remains unknown.

256 Studies of anesthesia for acute ischemic stroke suggested that inadequate brain pe

257 ectomy as Primary Endovascular Treatment for Acute Ischemic Stroke (SWIFT PRIME) trial in patients wi

258 Patients with acute ischemic stroke symptom onset 24 hours or less bef

259 e series or case reports of patients with an acute ischemic stroke that evaluated a neurothrombectomy

260 a clinical perspective for the treatment of acute ischemic stroke, these data suggest that helium 1)

261 ssed 50 consecutively admitted patients with acute ischemic stroke through reviews of abstracted data

262 activator (r-tPA) in eligible patients with acute ischemic stroke to improve patients' functional re

263 ithin 8 hours after the onset of symptoms of acute ischemic stroke to receive either medical therapy

264 The concept of neuroprotective therapy for acute ischemic stroke to salvage tissue at risk and impr

265 e 2013 guidelines on the early management of acute ischemic strokes to specifically incorporate the f

266 We examined 371 988 patients with acute ischemic stroke transported by EMS and enrolled in

267 A cohort analysis of 1193 patients having acute ischemic stroke treated with intravenous tPA betwe

268 Among patients with an acute ischemic stroke treated with intravenous tPA, thos

269 door-to-needle (DTN) times in patients with acute ischemic stroke treated with tissue-type plasminog

270 ndovascular therapy is a promising aspect of acute ischemic stroke treatment.

271 IAS) and Dose Escalation of Desmoteplase for Acute Ischemic Stroke Trial (DEDAS), and (b) another req

272 derived from the successful Desmoteplase in Acute Ischemic Stroke Trial (DIAS) and Dose Escalation o

273 ebo-controlled study involving patients with acute ischemic stroke using diffusion-weighted magnetic

274 r time from onset to recanalization (OTR) in acute ischemic stroke using endovascular therapy (ET) ha

275 of 5hmC in blood samples from patients with acute ischemic stroke was also significantly increased.

276 Tissue plasminogen activator (tPA) for acute ischemic stroke was approved by the U.S. Food and

277 claims data for Medicare beneficiaries with acute ischemic stroke was associated with considerably i

278 nctional outcome at 2 years in patients with acute ischemic stroke was similar to that reported at 90

279 s Treated With Neurothrombectomy Devices for Acute Ischemic Stroke) was a prospective, multicenter, o

280 n three hours after the onset of symptoms of acute ischemic stroke were at least 30 percent more like

281 Subjects with acute ischemic stroke were scanned with T2*-weighted MRI

282 death, acute myocardial infarction (AMI), or acute ischemic stroke, were evaluated over time.

283 y increased at 24 and 48 h in patients after acute ischemic stroke when compared to control values, w

284 rrhagic transformation (HT) in patients with acute ischemic stroke who receive intra-arterial thrombo

285 WIFT PRIME) trial in patients with disabling acute ischemic stroke who underwent endovascular therapy

286 ontrolled trial involving 1722 patients with acute ischemic stroke who were randomly assigned to rece

287 ng 12 months of follow-up, the patients with acute ischemic stroke who were treated with t-PA within

288 achieve its maximum potential, patients with acute ischemic stroke will have to be carefully selected

289 Endovascular treatment for acute ischemic stroke with a large vessel occlusion was

290 Among patients with acute ischemic stroke with a proximal vessel occlusion,

291 n addition to standard care in patients with acute ischemic stroke with a small infarct core, a proxi

292 Conclusion In the context of acute ischemic stroke with ipsilateral ICA nonattenuatio

293 To examine the prevalence of patients with acute ischemic stroke with known history of AF who were

294 ROCK activity is increased in patients after acute ischemic stroke with maximal activity occurring ab

295 arly valuable for treatment of patients with acute ischemic stroke with tissue plasminogen activator

296 T) compared with best medical management for acute ischemic strokes with large vessel occlusion (LVO)

297 tween May 1, 2010, and October 1, 2012, with acute ischemic stroke within 4.5 hours from symptom onse

298 issue plasminogen activator in patients with acute ischemic stroke within 6 h of onset.

299 o had a magnetic resonance imaging-confirmed acute ischemic stroke within the anterior circulation an

300 We randomly assigned 362 patients with acute ischemic stroke, within 4.5 hours after onset, to